Faruqi and Faruqui, LLP Logo
Share this page

Ocata Therapeutics, Inc. (OCAT)

NasdaqGM: OCAT


Faruqi & Faruqi, LLP Announces the Investigation of Ocata Therapeutics, Inc. (OCAT) Over the Proposed Sale of the Company to Astellas Pharma Inc.

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Ocata Therapeutics, Inc. (“Ocata” or the “Company”) (NasdaqGM: OCAT) for potential breaches of fiduciary duties in connection with the sale of the Company to Astellas Pharma Inc. for approximately $379 million.

The Company’s stockholders will only receive $8.50 per share in cash for each share of Company common stock they own. However the offer is below at least one analyst’s target price of $9.00 per share.

If you own common stock in Ocata and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330. 

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Ocata Therapeutics, Inc. (OCAT)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

MergerInfo Request
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 11/12/2015

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.